Evergreening is the term used for legal and technological
alternatives adopted by Pharmaceutical companies to extend their
exclusivity of over production and sale of patented medicines
beyond the prescribed statutory timeline of 20 years. The said
alternatives enable Pharma companies to retain royalties from
patented medicines by either taking out new patents over minor
incremental innovation, for example, associated delivery systems,
or new pharmaceutical mixtures with a hidden motive of extended
exclusivity over the main patented medicine beyond the prescribed
time
The main purpose of research and development for a pharma
company is to invent an entirely new medicine or a
'blockbuster' drug, which would disrupt the market in a
therapeutic domain. This blockbuster drug is aggressively patented
for varied compositions. Strictest of patent monopoly is enforced
by the company to prevent and more than often killing the
competition in such therapeutic domain. Hence, the